Tamtam Try Tamtam free
Stryker logo

Stryker account plan

Medical technology innovation

At a glance

Stryker is a global medical technology company in MedSurg, Neurotechnology and Orthopaedics, with FY2025 net sales of $25,116 million and ~56,000 employees.

Stryker is a global medical technology group offering surgical equipment and navigation, endoscopy, patient handling and emergency care, stroke and venous thromboembolism devices, joint replacement and trauma implants, and Mako robotic-arm assisted surgery. It sells in approximately 61 countries, mostly directly to doctors, hospitals and other healthcare facilities. FY2025 net sales were $25,116 million (+11.2% reported), with net earnings of $3,246 million and the United States accounting for $19,006 million of sales. It had approximately 56,000 employees at 31 December 2025.

Business units

Strategic priorities

Growth at the high end of MedTech
Stryker aims for sales growth at the high end of MedTech; 2026 guidance is 8.3%-9.3% organic sales growth and adjusted EPS of $14.95-$15.10.
Acquisitions first
Capital allocation prioritises acquisitions, then dividends, then buybacks; 2025 acquisitions cost $4,960 million, chiefly Inari, and AVS was bought in May 2026.
Robotics leadership
Mako 4, Mako Shoulder, Mako Total Hip revision and the Mako RPS handheld robot drive orthopaedics, where Stryker expects to outgrow the market by 200 to 300 basis points.
Margin expansion
The CFO remains committed to 150 basis points of operating margin expansion over 3 years.
Connected hospital and SmartCare
A new SmartCare unit combines Vocera and care.ai with beds in a Smart Hospital launch, alongside Connected OR integration.

Latest results

In Q2 2026 Stryker's net sales were $6,589 million, up 9.4% reported and 9.0% organic, with MedSurg and Neurotechnology at $3,625 million and Orthopaedics at $2,964 million. Adjusted EPS rose 17.9% to $3.69 and the adjusted operating margin rose 170 bps to 27.4%, helped by a reversal of 2025 tariffs. Six-month sales rose 6.1% to $12,609 million, a gap that reflects a cyber incident in Q1 2026 that halted production for almost 3 weeks. Stryker narrowed 2026 guidance to 8.3%-9.3% organic growth and adjusted EPS of $14.95-$15.10.

Investments and deals

Inari acquisition
Bought in February 2025 for $4,810 million net of cash, adding minimally invasive venous thromboembolism products to a new Peripheral Vascular business.
AVS acquisition
In May 2026 Stryker bought AVS, developing intravascular lithotripsy for peripheral arterial disease, for $435 million net cash plus up to $400 million in milestones.
Spinal Implants divestment
The Spinal Implants business was sold to Viscogliosi Brothers, LLC in April 2025.
Capex
Capex was $761 million in 2025 and $368 million in H1 2026.
Share buybacks
Stryker plans to resume buybacks in H2 2026, with $1,033 million of authorisation remaining.

Challenges and risks

Cyber incident recovery
A cyber incident first reported on 11 March 2026 caused "a global disruption to our business operations"; Stryker could not make product for almost 3 weeks.
Peripheral vascular supply disruption
A disruption at one Inari plant created a backorder with lost sales; US Vascular sales fell 6.7% in Q2 2026.
Tariffs, inflation and supply chain
Sole-source suppliers, US tariffs and inflation are named risks, along with oil and raw-material costs.
Pricing pressure
China's volume-based procurement, reimbursement changes and hospital consolidation create buyers with more bargaining power.
IT and regulatory change
Risks include the implementation of a new commercial global ERP system and EU MDR transition deadlines from May 2026 to December 2028.

What leadership says

“We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in the second quarter.”

Kevin A. Lobo, Chair and CEO · Q2 2026 earnings release, 30 July 2026

“All we have to do is make the products, and ship the products.”

Kevin A. Lobo, Chair and CEO · Q2 2026 earnings call, 30 July 2026

“we love our position as market leaders in robotics”

Kevin A. Lobo, Chair and CEO · Q1 2026 earnings call, 30 April 2026

“The Board and I have worked closely on a succession plan, and with our strong foundation in place, now is the right time for this leadership transition.”

Kevin A. Lobo, Chair and CEO · Leadership succession announcement, 6 October 2026

Where a supplier can help

Cybersecurity and IT resilience
After a cyber incident that wiped 40,000 laptops and halted production, and with a new global ERP rollout under way, security, backup and IT operations vendors address a named challenge.
Manufacturing and supply chain capacity
Elevated capital backlog, a peripheral vascular plant disruption and sole-source supplier risk point to demand for manufacturing, quality and supply chain partners.
M&A integration support
With acquisitions as the first capital priority and Inari integration described as challenging, integration and commercial onboarding services fit the acquisition priority.
Ambulatory surgery center build-out
Hip and knee procedures in ASCs are pushing 20 percent and the Mako RPS targets ASCs; construction, equipment and IT partners can support that robotics growth priority.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Stryker?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Stryker

What does Stryker do?

Stryker makes medical technology across MedSurg, Neurotechnology and Orthopaedics, including surgical equipment, endoscopy, patient handling, stroke and vascular devices, joint implants and Mako surgical robots.

What is Stryker's revenue?

FY2025 net sales were $25,116 million, up 11.2% reported; Q2 2026 net sales were $6,589 million.

How many employees does Stryker have?

Stryker had approximately 56,000 employees at 31 December 2025, approximately 28,000 of them in the US.

Who leads Stryker?

Kevin A. Lobo is Chair and CEO through 31 December 2026; Spencer S. Stiles, President and COO, becomes CEO on 1 January 2027, with Lobo as Executive Chair.

What is Stryker's strategy?

Stryker targets growth at the high end of MedTech, funded first by acquisitions, with robotics, vascular and connected-hospital products as main platforms.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)